Get the Stockscreener App
160.69
2.29%
4.11
Revolution Medicines Inc stock is traded at $160.69, with a volume of 1.23M.
It is up +2.29% in the last 24 hours and up +9.95% over the past month.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
See More
Previous Close:
$156.58
Open:
$156.75
24h Volume:
1.23M
Relative Volume:
0.41
Market Cap:
$34.09B
Revenue:
$742.00K
Net Income/Loss:
$-1.37B
P/E Ratio:
-22.72
EPS:
-7.0731
Net Cash Flow:
$-1.07B
1W Performance:
+11.08%
1M Performance:
+9.95%
6M Performance:
+108.70%
1Y Performance:
+309.20%
1-Day Range:
$156.44
$161.63
1-Week Range:
$143.47
$161.63
52-Week Range:
$34.00
$166.50
Revolution Medicines Inc Stock (RVMD) Company Profile
Name
Revolution Medicines Inc
Sector
Industry
Phone
650-481-6801
Address
700 SAGINAW DR, REDWOOD CITY, CA
Compare RVMD vs VRTX, REGN, ARGX, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
160.37 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.35 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
895.24 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
280.13 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-26 | Resumed | Jefferies | Buy |
| Feb-27-26 | Resumed | UBS | Buy |
| Nov-18-25 | Initiated | Wolfe Research | Outperform |
| Nov-03-25 | Initiated | RBC Capital Mkts | Outperform |
| Oct-21-25 | Initiated | Mizuho | Outperform |
| Oct-16-25 | Resumed | Stifel | Buy |
| Sep-12-25 | Resumed | Raymond James | Strong Buy |
| Sep-05-25 | Initiated | Truist | Buy |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Aug-15-25 | Initiated | Wells Fargo | Overweight |
| Jul-15-25 | Initiated | Goldman | Buy |
| Jul-16-24 | Reiterated | Needham | Buy |
| Jul-12-24 | Initiated | Barclays | Overweight |
| Jul-08-24 | Initiated | Jefferies | Buy |
| Apr-12-24 | Reiterated | Needham | Buy |
| Apr-10-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-11-24 | Initiated | Piper Sandler | Overweight |
| Jan-05-24 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-04-24 | Initiated | Wedbush | Outperform |
| Nov-16-23 | Initiated | Raymond James | Outperform |
| Feb-28-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-14-22 | Initiated | Needham | Buy |
| Oct-21-22 | Initiated | Oppenheimer | Outperform |
| May-20-22 | Initiated | BofA Securities | Neutral |
| Mar-01-22 | Upgrade | Stifel | Hold → Buy |
| Sep-23-21 | Initiated | Stifel | Hold |
| Aug-12-21 | Downgrade | Goldman | Buy → Neutral |
| May-18-21 | Initiated | Goldman | Buy |
| May-21-20 | Initiated | H.C. Wainwright | Buy |
| Mar-09-20 | Initiated | Cowen | Outperform |
| Mar-09-20 | Initiated | Guggenheim | Buy |
| Mar-09-20 | Initiated | JP Morgan | Neutral |
View All
Revolution Medicines Inc Stock (RVMD) Latest News
Revolution Medicines (RVMD) Is Up 7.8% After Phase 3 Survival Data Validates RAS(ON) Strategy - simplywall.st
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Erasca, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss -- HBSS - GlobeNewswire Inc.
Revolution Medicines (NASDAQ: RVMD) insider sells 132,871 shares totaling $19.29M - Stock Titan
Revolution Medicines (NASDAQ: RVMD) affiliate reports sale of 2,958 shares under Rule 144 - Stock Titan
Revolution Medicines (NASDAQ: RVMD) insider sale of 2,753 shares for $273,869.54 - Stock Titan
Revolution Medicines (NASDAQ: RVMD) insider sales total 43,691 shares reported - Stock Titan
Stephen M. Kelsey (RVMD) files to sell 4,071 restricted shares; prior 4,302 sold - Stock Titan
Insider sale: Margaret Horn notifies sale of 14,583 RVMD shares (RVMD) - Stock Titan
RVMD: 90,000 shares registered for sale after option exercise (RVMD) - Stock Titan
[Form 4] Revolution Medicines, Inc. Insider Trading Activity - Stock Titan
Why is Revolution Medicines (RVMD) up 9.3% since last earnings report? - MSN
Pancreatic Cancer Drug Milestone Affirms Why Revolution Medicines Inc. (RVMD) is a Hot Stock to Buy - Yahoo Finance
Revolution Medicines upgraded to buy after Dara... | Pluang – Crypto, Stocks, Gold & Funds - Pluang
Revolution Medicines: Strong Data, Big Market (Rating Upgrade) - Seeking Alpha
Revolution Medicines (RVMD) Stock After RASolute 302 Phase 3 Success A Fresh Look At Valuation - simplywall.st
Number of shareholders of Revolution Medicines, Inc. – NASDAQ:RVMDW - TradingView
‘Pharma Bro’ Martin Shkreli Defends Revolution Medicines’ Pancreatic Cancer Study Data: ‘Progress Compounds’ - Stocktwits
Bernstein initiates coverage of Revolution Medicines (RVMD) with market perform recommendation - MSN
Daraxonrasib’s Phase 3 Pancreatic Cancer Survival Data Might Change The Case For Investing In RVMD - Yahoo Finance
RVMD: Insider files Form 144 to sell 10,000 shares (NASDAQ: RVMD) - Stock Titan
Can Revolution Medicines Be a Game-Changer Stock? - The Motley Fool
RVMD Maintained by Evercore ISI Group -- Price Target Raised to $220 - GuruFocus
Revolution Medicines Inc. Warrant (RVMDW) Edges Higher Amid Modest Trading ActivityFibonacci Entry Signals - newsline.com
Tango shares surge on early pancreatic cancer combination data - The Pharma Letter
UBS Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $175 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Tango Dances Toward Phase III With Positive Vopimetostat/Daraxonrasib Data - Citeline News & Insights
Revolution Medicines (RVMD) Reports Promising Data on Vopimetost - GuruFocus
Tango Therapeutics Stock Soars 53% After ’Unprecedented’ Data on Pancreatic Cancer Treatment - Barron's
Biotech Surges 45% On Eye-Popping Pancreatic Cancer Test - Investor's Business Daily
Revolution Medicines (RVMD) Strengthens PDAC Position with New D - GuruFocus
‘WOW!’: RevMed and Tango’s pancreatic cancer combo achieves 92% response - BioSpace
Is Revolution Medicines (RVMD) The Best Biotech Stock According to Billionaire Stanley Druckenmiller? - Insider Monkey
Why Revolution Medicines (RVMD) Is Down 8.8% After Phase 3 Daraxonrasib Pancreatic Cancer Survival Data Release And What's Next - simplywall.st
J&J spends $1 billion to enter KRAS race for cancer treatments - statnews.com
Combination of pancreatic cancer drugs from Tango, Revolution leads to high response rate - statnews.com
Revolution Medicines, Inc. (RVMD) Stock Analysis: Unlocking a 24.86% Upside Amidst Biotech Breakthroughs - DirectorsTalk Interviews
Total equity of Revolution Medicines, Inc. – XETR:42Z - TradingView
Debt to assets ratio of Revolution Medicines, Inc. – XETR:42Z - TradingView
ETFs Investing in Revolution Medicines, Inc. Stocks - TradingView
(RVMD) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Earnings call transcript: Revolution Medicines Q1 2026 focuses on strong cash position - Investing.com
Revolution Medicines (RVMD) Drops 4% as Biotech Sector Faces Renewed PressureTrading Ideas - newsline.com
Revolution Medicines in the spotlight for earnings post-trial win By Investing.com - Investing.com Nigeria
Why Is Revolution Medicines (RVMD) Up 9.3% Since Last Earnings Report? - Yahoo Finance
Novo vet Uli Stilz settles in at Flagship; Revolution Medicines welcomes commercial exec - Endpoints News
California Pharma Co. Tests Breakthrough Cancer Drug, Cuts Death Risk 60% - Streetwise Reports
Revolution Medicines is up 97% this year: Here are the bull and bear cases for this soaring biotech stock - MSN
Revolution Medicines Stock Surges on Promising Cancer Drug Data - IndexBox
Revolution Medicines Is Up 97% This Year: Here Are the Bull and Bear Cases for This Soaring Biotech Stock. - The Motley Fool
Revolution Medicines Inc Stock (RVMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):